Takeda Oncology
Jean (Morrone) Tremarche is an experienced leader in pharmacovigilance and medical safety, currently serving as Associate Director of Medical Safety Oncology at Takeda Oncology since January 2020. With a strong background at Alkermes as Associate Director of Safety Signaling and Aggregate Reporting, Jean led a team of pharmacovigilance scientists to support clinical development and post-marketing safety initiatives. Previous roles include Pharmacovigilance Scientist at Sanofi Genzyme, Clinical Safety Manager at AMAG Pharmaceuticals, and Clinical Safety Manager at Enobia Pharma, among others. Jean has also contributed to academia as a part-time lecturer at Northeastern University and possesses a BA in Biology from the University of Connecticut, supplemented by a certificate in HMX Fundamentals from Harvard Medical School.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.